Biotech · United States
Zephyr AI
Precision Medicine Powered by AI
- Community votes
- 0
- DR by Ahrefs
- 40 +1 (up) since last check
Ahrefs Domain Rating reviewed on 4 Nov 2026, a new score on 29 Oct 2026.
Zephyr AI transforms real-world data into actionable insights for drug discovery and diagnostics using multi-modal AI and enterprise-scale clinicogenomic data.
Synopsis
The Zephyr AI homepage
Zephyr AI combines advanced machine learning with enterprise-scale real-world data to advance precision medicine. The platform integrates multi-modal AI, clinicogenomic datasets, and secure infrastructure to help biopharma and diagnostics companies accelerate drug development, validate biomarkers, and improve patient stratification across the therapeutic lifecycle.
The company's AIM Suite provides modular, interpretable AI tools for predicting drug response using clinical data without requiring new assays. Nexus transforms electronic health records, claims, genomics, and pathology data into actionable insights. Zephyr provides access to one of the world's largest oncology cohorts through Aster Insights and the ORIEN Total Cancer Care study, with 400K+ lifetime-consented patients and deeply profiled cancer data.
Built on three core principles—learn from a lot, refine with a little, and enrich limited patient data with deep biological context—Zephyr's platform is designed to integrate seamlessly into existing R&D and clinical workflows with SOC 2 and HIPAA compliance.
On the bill
- AIM Suite: multi-modal AI modules for predicting drug response
- Nexus: real-world data analytics platform for EHR, claims, genomics, and pathology
- Access to 400K+ lifetime-consented oncology patients through Aster Insights and ORIEN
- Aster Avatar: matched clinical, exome, transcriptome, and digital pathology data
- SOC 2 and HIPAA compliant infrastructure
- AIM-CDx: fine-tuned companion diagnostics co-developed with partners
- AIM-Ex: reconstructs mRNA expression from DNA data and minimal clinical data
- Cohort construction and synthetic controls for clinical trials
Zephyr AI metrics
| Metric | Value |
|---|---|
| Domain Rating | 40 +1 (up) since last check |
| Trust Flow | 13 no change since last check |
| Citation Flow | 17 no change since last check |
| Referring domains | 140 no change since last check |
| External backlinks | 410 no change since last check |
Ahrefs Domain Rating reviewed on 4 Nov 2026, a new score on 29 Oct 2026. Its best-known topic: Business/Management (13). Majestic reviewed on 26 Oct 2026, a new score on 26 Oct 2026. Link data credited to Majestic. Trust Flow, Citation Flow and Topical Trust Flow are trademarks of Majestic-12 Ltd.
Zephyr AI's domain, behind the curtain
Look behind the curtain
| Domain age | 5 years |
|---|---|
| Registered | |
| Expires | |
| Registrar | Amazon Registrar, Inc. |
| DNSSEC | Signed |
Zephyr AI's reviews after opening night
Zephyr AI went live on Product Debuts on 26 October 2026. Here is what our readings show since then.
- Domain Rating (Ahrefs)
- 40 +1 (up) since launch
- 39 at launch (26 Oct 2026), 40 on 3 Nov 2026
- Trust Flow (Majestic)
- 13
- First measured 26 Oct 2026
- Referring domains (Majestic)
- 140
- First measured 26 Oct 2026
Day 8 since launch. Next receipt: day 30, 25 Nov 2026. What the readings say, nothing more: a rise or fall here is not proof of its cause. We leave out anything we have not measured.
Compare and explore
Press questions
What is the AIM Suite?
The AIM Suite is a set of modular, biologically interpretable AI tools designed to integrate seamlessly into R&D workflows without requiring new assays. Each module can operate independently or be combined to give partners flexibility in tailoring solutions to their drug development or clinical needs.
What is Aster Avatar?
Aster Avatar provides matched clinical, exome, transcriptome, and digital pathology data with longitudinal updates, ideal for translational research and biomarker discovery as part of Zephyr's access to one of the world's largest and most deeply profiled oncology resources.
Leave a review for Zephyr AI
Zephyr AI is waiting for its first review. Take the stage.
Reviews are free. Nobody pays to be reviewed here. See the reviews and chat
Reviews and buzz · Since opening night · Share the debut · Your company on stage? Claim it · Report this debut
Zephyr AI has a free listing. The owner can unlock the full profile with a paid launch for $5:
- Founder story (locked)
- Milestones (locked)
- Demo video (locked)
- Dofollow website link (locked)